Syros Pharmaceuticals, Inc. (SYRS) Financial Ratios
11 years of historical data (2013–2023) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.00
↓-100% vs avg
5yr avg: 5.00
30Y Low0.4·High13.2
ROE
↓
-227.9%
↑-87% vs avg
5yr avg: -122.0%
30Y Low-233%·High-42%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
SYRS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2683 | $221M | $45M | $204M | $500M | $278M | $182M | $247M | $154M | — | — |
| Enterprise Value | $-77448317 | $143M | $-58547235 | $177M | $392M | $262M | $132M | $215M | $96M | — | — |
| P/E Ratio → | 0.00 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.00 | 22.21 | 3.05 | 8.68 | 33.11 | 140.23 | 88.73 | 224.53 | 487.03 | — | — |
| P/B Ratio | 0.00 | 13.24 | 0.36 | 2.39 | 5.52 | 3.51 | 2.31 | 3.78 | 1.92 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
SYRS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 14.41 | -3.93 | 7.53 | 25.96 | 132.40 | 64.41 | 195.33 | 302.91 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
SYRS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Syros Pharmaceuticals, Inc. earns an operating margin of -1298.2%. Operating margins have compressed from -423.3% to -1298.2% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -227.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.3% | 77.3% | 80.1% | 100.0% | 100.0% | 100.0% | 100.0% | -38.7% | 100.0% | -89.9% | — |
| Operating Margin | -1298.2% | -1298.2% | -913.1% | -423.3% | -545.3% | -3922.4% | -3136.4% | -4966.9% | -15130.3% | -9406.9% | — |
| Net Profit Margin | -1656.3% | -1656.3% | -636.1% | -368.5% | -556.8% | -3806.2% | -3038.0% | -4905.5% | -15060.9% | -9406.3% | — |
Return on Capital
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -227.9% | -227.9% | -88.9% | -98.5% | -99.0% | -95.6% | -86.6% | -74.0% | -83.3% | -63.2% | -41.8% |
| ROA | -79.8% | -79.8% | -44.3% | -43.7% | -46.3% | -58.8% | -67.2% | -63.6% | -70.8% | -56.7% | -40.4% |
| ROIC | — | — | -248.7% | -364.7% | -265.8% | -126.2% | -155.8% | -148.0% | -347.3% | — | -100762.5% |
| ROCE | -74.7% | -74.7% | -74.4% | -59.2% | -52.9% | -72.8% | -83.9% | -74.0% | -81.7% | -62.2% | -41.8% |
SYRS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $140M exceeds total debt of $62M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 3.73 | 3.73 | 0.50 | 0.76 | 0.73 | 0.33 | 0.00 | 0.00 | 0.00 | 0.01 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -4.65 | -0.81 | -0.32 | -1.19 | -0.20 | -0.63 | -0.49 | -0.72 | -1.04 | -1.00 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -31.10 | -31.10 | -21.90 | -21.15 | -45.90 | — | -62279.00 | — | — | — | — |
Net cash position: cash ($140M) exceeds total debt ($62M)
SYRS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Syros Pharmaceuticals, Inc.'s current ratio of 3.95x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.33x to 3.95x over the past 3 years.
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.95 | 3.95 | 6.87 | 4.33 | 6.24 | 4.87 | 5.21 | 5.89 | 8.94 | 4.58 | 48.36 |
| Quick Ratio | 3.95 | 3.95 | 6.87 | 4.33 | 6.24 | 4.86 | 5.21 | 5.89 | 8.94 | 4.58 | 48.36 |
| Cash Ratio | 3.80 | 3.80 | 6.57 | 4.14 | 6.08 | 3.89 | 5.10 | 5.80 | 8.74 | 4.51 | 48.24 |
| Asset Turnover | — | 0.06 | 0.06 | 0.13 | 0.07 | 0.01 | 0.02 | 0.01 | 0.00 | 0.01 | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 41.55 | 46.29 | 56.37 | 3712.25 | — | — | 998.28 | — | — |
SYRS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Syros Pharmaceuticals, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $28M | $13M | $6M | $5M | $4M | $3M | $3M | $1M | $247557 | $247557 |
Peer Comparison
Compare SYRS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 SYRSYou | $2683 | 0.0 | — | — | 77.3% | -1298.2% | -227.9% | — | — |
 KYMR | $8B | -27.0 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ARVN | $499M | -6.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 IMVT | $8B | -13.8 | — | — | — | — | -64.8% | — | — |
 TNGX | $3B | -32.8 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 PRAX | $9B | -22.5 | — | — | — | — | -45.8% | -65.0% | — |
 RVMD | $35B | -27.9 | — | — | — | — | -58.1% | -54.3% | — |
 BEAM | $4B | -43.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $274M | -1.6 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 NTLA | $2B | -4.1 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 CRSP | $5B | -8.4 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.4 | 63.9% | -4.4% | -33.2% | -11.7% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 11 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
SYRS — Frequently Asked Questions
Quick answers to the most common questions about buying SYRS stock.
What is Syros Pharmaceuticals, Inc.'s P/E ratio?
Syros Pharmaceuticals, Inc.'s current P/E ratio is 0.0x.
What is Syros Pharmaceuticals, Inc.'s ROE?
Syros Pharmaceuticals, Inc.'s return on equity (ROE) is -227.9%. The historical average is -108.4%.
Is SYRS stock overvalued?
Based on historical data, Syros Pharmaceuticals, Inc. is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.
What are Syros Pharmaceuticals, Inc.'s profit margins?
Syros Pharmaceuticals, Inc. has 77.3% gross margin and -1298.2% operating margin.